Related Experiment Video
Updated: Feb 21, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Recombinant live biotherapeutics against chronic metabolic diseases: Challenges and opportunities
Prajwal Swamy1, Lakhwinder Singh2, Priya Sehrawat1
1Chemistry & Pharmacology lab, Centre for Drug Discovery, BRIC, Translational Health Sciences and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Abstract:
Chronic metabolic diseases (CMDs) such as obesity, type 2 Diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiovascular diseases (CVDs) represent an escalating global health crisis. The etiology and pathophysiology of CMDs are linked to persistent metabolic, inflammatory, and gut microbiome dysfunctions. Recombinant Live Biotherapeutic Products (rLBPs) are engineered microbes designed to deliver targeted metabolic, anti-inflammatory, or hormonal effects in situ, offering a promising alternative to conventional therapies. The development of the rLBPs is expected to bring a paradigm shift in the clinical management of chronic diseases. This chapter provides an overview of rLBPs by highlighting seminal examples of rLBPs, which are in the early phase of development for CMDs. It also deliberates on existing scientific, technical and regulatory challenges along with potential opportunities associated with the development of rLBPs.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Drug Products: Biologics, Biosimilars and Interchangeables
Recombinant DNA
The Central Dogma
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
Pharmacogenomics: Identification of New Drug Targets
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

